L362V

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card

Leucine → Valine at position 362 · Lumenal loop 1 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type L362 — hydrogen bond to Q366

Fullscreen ↗

DynaMut2 mutant · L362V

Mutant V362 — hydrogen bond contact to V358 lost

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost0 gained10 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	V358	V358	Preserved
Hydrogen bond	I359	I359	Preserved
Hydrogen bond	F365	F365	Preserved
Hydrogen bond	Q366	Q366	Preserved
Polar contact	V358	V358	Preserved
Polar contact	I359	I359	Preserved
Polar contact	F365	F365	Preserved
Polar contact	Q366	Q366	Preserved
Van der Waals	V358	—	Lost
Hydrophobic	V358	V358	Preserved
Hydrophobic	F439	F439	Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-0.23kcal/mol

Destabilising — mild

AlphaMissense

0.671

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, single submitter

Associated conditionsAutosomal dominant nonsyndromic hearing loss 6

Population frequency (gnomAD v4)Ultra-rare · AF 0.00025%

cDNA changec.1084C>G

ClinVar accessionVCV004293849

Last evaluated2024/10/31 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — L362V Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Leucine → Valine at position 362. Lumenal loop 1. ClinVar Uncertain significance, AlphaMissense 0.671, DynaMut2 ΔΔG -0.23 kcal/mol (destabilising).

Identity

Field	Value
Variant	L362V (p.Leucine362Valine)
DNA change	c.1084C>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV004293849
Amino acid change	Leucine (L) → Valine (V)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 362	88.44 — well-folded
Domain	Lumenal loop 1
Position context	C-terminal lumenal domain · position 362 projects into the ER lumen
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 362 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is medium hydrophobic (leucine — branched); the mutant is small hydrophobic (valine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.6714
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-0.23 (Destabilising)
Job ID	178092126878
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092126878

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, single submitter
Last evaluated	2024/10/31 00:00
Inheritance	Autosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscape	L362V is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

Autosomal dominant nonsyndromic hearing loss 6

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.23 < 2 kcal/mol (fold intact) + AlphaMissense 0.671 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.23 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.671. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
L362V_molstar_viewer.html — interactive 3D viewer (auto-highlights position 362 with ball-and-stick + neighbors within 5Å)
L362V_variant_card.md — this card (source of truth)
L362V_variant_card.html — styled printable card
L362V_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
L362V_wildtype_interactions.pse / L362V_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the L362V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download L362V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.